Physician profile
Thomas Smith
NPI 1952372112
$182,187.48
in general payments reported to CMS, 2019-2025
64 companies · $30K in 2025
The $30K reported for 2025 was more than what 94% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $29K · 2020: $27K · 2021: $23K · 2022: $25K · 2023: $22K · 2024: $27K · 2025: $30K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $68K · Food and Beverage: $5,021 · Consulting Fee: $2,700 · Travel and Lodging: $1,706 · Education: $550.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $68,174.00 |
| Food and Beverage | $5,020.94 |
| Consulting Fee | $2,700.00 |
| Travel and Lodging | $1,705.73 |
| Education | $550.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $97,600.20 | 2019-2025 | Ubrelvy, Qulipta, Vraylar |
| Genzyme Corporation | $24,512.31 | 2019-2022 | |
| Allergan, INC. | $23,055.63 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $14,965.25 | 2019-2023 | Austedo Xr |
| E.R. Squibb & Sons, L.L.C. | $8,722.03 | 2024-2025 | Zeposia |
| Celgene Corporation | $4,150.39 | 2021-2025 | Zeposia |
| Alexion Pharmaceuticals, INC. | $1,212.37 | 2019-2025 | Ultomiris |
| Ucb, INC. | $794.87 | 2019-2025 | Briviact |
| Biogen, INC. | $676.86 | 2019-2023 | Tysabri, Vumerity |
| Novartis Pharmaceuticals Corporation | $601.60 | 2019-2023 | |
| Sk Life Science, INC. | $428.27 | 2021-2024 | Xcopri |
| Amgen INC. | $369.21 | 2019-2025 | Uplizna |
| Emd Serono, INC. | $343.68 | 2019-2023 | Mavenclad |
| Biohaven Pharmaceuticals, INC. | $339.76 | 2021 | |
| Genentech USA, INC. | $328.86 | 2019-2023 | Enspryng, Ocrevus, Evrysdi |
Show all 64 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.